Join us on Mon 3rd Feb 2025 for World Aspergillosis Day to help raise awareness and connect with others who have an interest in this disease. By working together, we can improve diagnosis, treatment and support for aspergillosis patients around the world  #WorldAspergillosisDay  #WAD2025

 

On Mon 3rd Feb, we will be running a 1-day online meeting via Microsoft Teams, where people can share lived experiences and learn about cutting-edge developments in chronic aspergillosis. Please register here to receive the joining instructions. Run by the CARES team at the National Aspergillosis Centre (Manchester, UK), this meeting hopes to bring together doctors, researchers and patients living with chronic forms of aspergillosis (CPA, aspergilloma, nodules, ABPA, SAFS).

 

PROGRAMME

The full programme will be made available in January and will be divided into the following sections, which have themes based on some of the questions most commonly asked in our patient support group:

  • Why did I get CPA? Genetics, immunology & lung damage
  • Is my treatment working? Lab tests & quality of life questionnaires
  • What if I develop azole resistance? Treatment failure & new antifungals

There will be time to socialise/network during coffee and lunch breaks, and we can provide separate breakout rooms if you would like

 

————————————————————————————————-

TECHNOLOGY

  • Microsoft Teams is free for personal use and can be downloaded here: www.microsoft.com/en-gb/microsoft-teams/teams-for-home
  • We recommend installing it a week or two before the event, in case you have problems setting it up. Ideally do a practice call with a friend/family member.
  • The talks will also be available on-demand via our YouTube channel after the event.

 

————————————————————————————————-

 

DISCLAIMER

  • The information presented at this meeting does not constitute medical advice and we will not be able to give personal medical advice to any attendees.
  • This event is intended for patients with a medical diagnosis of chronic aspergillosis such as CPA, ABPA, aspergilloma, nodules or similar. Please keep in mind that aspergillosis is an extremely variable condition and not all of the information presented will be relevant to all patients in all healthcare systems.
  • People who have experienced other serious fungal conditions (e.g. invasive aspergillosis, Valley Fever, mucormycosis, Scedosporium infection) may find this meeting interesting, although we will not be covering these diagnoses directly.
  • We will not be discussing more controversial topics such as toxic mold or Candida overgrowth, and we will not allow attendees to promote alternative therapies that we think are potentially harmful (e.g. colloidal  silver, restrictive diets, essential oils)